공고 • Jun 04
Pure Biologics S.A., Annual General Meeting, Jun 29, 2026 Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time. New Risk • Dec 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Shares are highly illiquid. Negative equity (-zł18m). Earnings have declined by 6.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€7.85m market cap, or US$9.12m). 공고 • Nov 11
Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025 Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025 공고 • Aug 21
Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025 Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025 공고 • Jun 05
Pure Biologics S.A., Annual General Meeting, Jun 28, 2024 Pure Biologics S.A., Annual General Meeting, Jun 28, 2024. Reported Earnings • Nov 19
Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022) Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022). Reported Earnings • Sep 03
Second quarter 2023 earnings released Second quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022). Reported Earnings • May 21
First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022) First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022). 공고 • May 09
Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023 Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time. Reported Earnings • Sep 18
Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021) Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. 공고 • May 25
Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022 Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022, at 10:00 Central European Standard Time. Reported Earnings • Apr 02
Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020) Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 129% growth forecast for the pharmaceuticals industry in Germany. Reported Earnings • Nov 19
Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020) Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020). Reported Earnings • Sep 15
Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020) Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020). Is New 90 Day High Low • Jan 09
New 90-day high: €25.80 The company is up 45% from its price of €17.80 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: €25.00 The company is up 7.0% from its price of €23.40 on 19 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: zł1.60 loss per share Third quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019). Is New 90 Day High Low • Oct 30
New 90-day low: €15.05 The company is down 33% from its price of €22.50 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. Is New 90 Day High Low • Sep 26
New 90-day low: €18.25 The company is down 14% from its price of €21.10 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. 
